Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

Lonza awarded second NIH iPSC contract
April 2013
SHARING OPTIONS:

WALKERSVILLE, Md.Lonza Walkersville Inc. has been awarded a contract by the U.S. National Institutes of Health Center for Regenerative Medicine (NIH CRM) to generate induced pluripotent stem cells (iPSCs) for research purposes. This represents the second contract that Lonza has been awarded by the NIH for generating iPSCs, the first originating in October 2012 when Lonza was contracted to produce clinical-grade iPSCs under current Good Manufacturing Practices. The current NIH CRM contract is known as an Indefinite Delivery/Indefinite Quantity award, which provides an indefinite quantity of services for a fixed amount of time. Lonza's contract is a three-year agreement with a total value of up to $6.9 million.
 
Stephan Kutzer, chief operating officer at Lonza Pharma-Biotech, commented that "this latest NIH contract validates Lonza's investments in this key strategic area."

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.